Cardiovascular disease remains a major cause of death and disability in developed countries and, increasingly so, in the developing world. Presented in this volume of Advances in Pharmacology are some of the most promising possibilities for treating large numbers of individuals afflicted with these conditions
This volume contains up-to-date reviews of the most important emerging cardiovascular therapies written by world leaders in the field.
1. I. Introduction 2. II. Cardiovascular Physiology of ET-1 3. III. Conclusion 4. Acknowledgments 5. Vascular Pharmacology of Epoxyeicosatrienoic Acids 6. Abbreviations 7. I. Introduction 8. II. Biochemistry 9. III. EETs and Vascular Tone 10. IV. EETs and Inflammation 11. V. EETs and Angiogenesis 12. VI. Conclusion 13. Acknowledgment 14. Prostaglandins in Action 15. I. Introduction 16. II. COX Isozymes 17. III. COX-1 and COX-2 in Patho/Physiological States 18. IV. Controversies over COX-2 Inhibitors and Cardiovascular Events 19. V. Conclusion 20. Acknowledgments 21. TP Receptors and Oxidative Stress 22. Abbreviations 23. I. Introduction 24. II. Arachidonic Acid Derivatives and Oxidative Stress 25. III. Vascular Function 26. IV. Vascular Inflammation 27. V. Atherosclerosis 28. VI. Implications for Clinical Usefulness of TP Antagonists 29. Acknowledgments 30. Regulation of Endothelial Cell Tetrahydrobiopterin 31. Abbreviations 32. I. Introduction 33. II. Chemistry and Synthesis of Pterins 34. III. The Role of BH4 in NOS Function—Concept of NOS Uncoupling 35. IV. NOS Uncoupling in Diseases 36. V. Structural Characteristics of GTPCH-1 and Posttranslational Modulation 37. VI. Conclusion 38. Acknowledgments 39. Polyphenol-Induced Endothelium-Dependent Relaxations 40. Abbreviations 41. I. Introduction: The Epidemiological Evidence 42. II. Polyphenols Induce Endothelium-Dependent Responses In Vitro and Ex Vivo 43. III. Polyphenols and Endothelial Function In Vivo 44. IV. Conclusion 45. Organic Nitrates and Nitrate Tolerance—State of the Art and Future Developments 46. Abbreviations 47. I. Introduction 48. II. The Phenomenon of Nitrate Tolerance 49. III. Oxidative Stress 50. IV. Bioactivation of Organic Nitrates 51. V. Strategies to Overcome Nitrate Tolerance 52. VI. New Nitrates 53. VII. Conclusion, Outlook, and Clinical Relevance 54. Acknowledgments 55. Vascular Actions of Adipokines 56. Abbreviations 57. I. Introduction 58. II. Cross-Talk Between Adipose Tissue and Blood Vessels 59. III. Modulation of Vascular Function by Adipokines 60. IV. Adiponectin and A-FABP as Therapeutic Targets for Vascular Diseases 61. V. Conclusion 62. Acknowledgments 63. Cardiovascular Effects of Erythropoietin 64. Abbreviations 65. I. Introduction 66. II. Pharmacokinetics of Erythropoietin 67. III. Signal Transduction by Erythropoietin 68. IV. Mechanisms of Vascular Protective Effects of Erythropoietin 69. V. Erythropoietin and Cardioprotection 70. VI. Erythropoietin and Cerebrovascular Disorders 71. VII. Erythropoietin and Progenitor Cells 72. VIII. Conclusion 73. Acknowledgments
Cardiovascular disease remains a major cause of death and disability in developed countries and, increasingly so, in the developing world. Presented in this volume of Advances in Pharmacology are some of the most promising possibilities for treating large numbers of individuals afflicted with these conditions
This volume contains up-to-date reviews of the most important emerging cardiovascular therapies written by world leaders in the field.
1. I. Introduction 2. II. Cardiovascular Physiology of ET-1 3. III. Conclusion 4. Acknowledgments 5. Vascular Pharmacology of Epoxyeicosatrienoic Acids 6. Abbreviations 7. I. Introduction 8. II. Biochemistry 9. III. EETs and Vascular Tone 10. IV. EETs and Inflammation 11. V. EETs and Angiogenesis 12. VI. Conclusion 13. Acknowledgment 14. Prostaglandins in Action 15. I. Introduction 16. II. COX Isozymes 17. III. COX-1 and COX-2 in Patho/Physiological States 18. IV. Controversies over COX-2 Inhibitors and Cardiovascular Events 19. V. Conclusion 20. Acknowledgments 21. TP Receptors and Oxidative Stress 22. Abbreviations 23. I. Introduction 24. II. Arachidonic Acid Derivatives and Oxidative Stress 25. III. Vascular Function 26. IV. Vascular Inflammation 27. V. Atherosclerosis 28. VI. Implications for Clinical Usefulness of TP Antagonists 29. Acknowledgments 30. Regulation of Endothelial Cell Tetrahydrobiopterin 31. Abbreviations 32. I. Introduction 33. II. Chemistry and Synthesis of Pterins 34. III. The Role of BH4 in NOS Function—Concept of NOS Uncoupling 35. IV. NOS Uncoupling in Diseases 36. V. Structural Characteristics of GTPCH-1 and Posttranslational Modulation 37. VI. Conclusion 38. Acknowledgments 39. Polyphenol-Induced Endothelium-Dependent Relaxations 40. Abbreviations 41. I. Introduction: The Epidemiological Evidence 42. II. Polyphenols Induce Endothelium-Dependent Responses In Vitro and Ex Vivo 43. III. Polyphenols and Endothelial Function In Vivo 44. IV. Conclusion 45. Organic Nitrates and Nitrate Tolerance—State of the Art and Future Developments 46. Abbreviations 47. I. Introduction 48. II. The Phenomenon of Nitrate Tolerance 49. III. Oxidative Stress 50. IV. Bioactivation of Organic Nitrates 51. V. Strategies to Overcome Nitrate Tolerance 52. VI. New Nitrates 53. VII. Conclusion, Outlook, and Clinical Relevance 54. Acknowledgments 55. Vascular Actions of Adipokines 56. Abbreviations 57. I. Introduction 58. II. Cross-Talk Between Adipose Tissue and Blood Vessels 59. III. Modulation of Vascular Function by Adipokines 60. IV. Adiponectin and A-FABP as Therapeutic Targets for Vascular Diseases 61. V. Conclusion 62. Acknowledgments 63. Cardiovascular Effects of Erythropoietin 64. Abbreviations 65. I. Introduction 66. II. Pharmacokinetics of Erythropoietin 67. III. Signal Transduction by Erythropoietin 68. IV. Mechanisms of Vascular Protective Effects of Erythropoietin 69. V. Erythropoietin and Cardioprotection 70. VI. Erythropoietin and Cerebrovascular Disorders 71. VII. Erythropoietin and Progenitor Cells 72. VIII. Conclusion 73. Acknowledgments
